Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central anxious procedure, conolidine modulates alternate molecular targets. A Science Improvements review located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,… Read More